IN2014DN10576A - - Google Patents

Info

Publication number
IN2014DN10576A
IN2014DN10576A IN10576DEN2014A IN2014DN10576A IN 2014DN10576 A IN2014DN10576 A IN 2014DN10576A IN 10576DEN2014 A IN10576DEN2014 A IN 10576DEN2014A IN 2014DN10576 A IN2014DN10576 A IN 2014DN10576A
Authority
IN
India
Prior art keywords
bruton
inhibitors
compositions
useful
same
Prior art date
Application number
Other languages
English (en)
Inventor
Brian T Hopkins
Patrick Conlon
Timothy R Chan
Tracy J Jenkins
Xiongwei Cai
Michael Humora
Xianglin Shi
Ross A Miller
Andrew Thompson
Original Assignee
Biogen Idec Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc
Publication of IN2014DN10576A publication Critical patent/IN2014DN10576A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
IN10576DEN2014 2012-06-08 2013-06-07 IN2014DN10576A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10576A true IN2014DN10576A (ko) 2015-08-28

Family

ID=49712704

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10576DEN2014 IN2014DN10576A (ko) 2012-06-08 2013-06-07

Country Status (30)

Country Link
US (5) US9394277B2 (ko)
EP (3) EP2858499B1 (ko)
JP (6) JP6214643B2 (ko)
KR (4) KR20200043497A (ko)
CN (3) CN113549055A (ko)
AR (1) AR091273A1 (ko)
AU (5) AU2013271407B2 (ko)
BR (2) BR112014030655B1 (ko)
CA (2) CA3108186A1 (ko)
CY (1) CY1120638T1 (ko)
DK (1) DK2858499T3 (ko)
EA (2) EA027823B1 (ko)
ES (2) ES2834333T3 (ko)
HK (1) HK1209284A1 (ko)
HR (1) HRP20181294T1 (ko)
HU (1) HUE039897T2 (ko)
IL (2) IL235938B (ko)
IN (1) IN2014DN10576A (ko)
LT (1) LT2858499T (ko)
MX (2) MX363672B (ko)
NZ (1) NZ702715A (ko)
PH (2) PH12014502699B1 (ko)
PL (1) PL2858499T3 (ko)
PT (1) PT2858499T (ko)
RS (1) RS57978B1 (ko)
SG (2) SG11201408173WA (ko)
SI (1) SI2858499T1 (ko)
TW (3) TWI592406B (ko)
WO (1) WO2013185084A1 (ko)
ZA (1) ZA201409255B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473049B1 (en) 2009-09-04 2018-11-28 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2858500A4 (en) * 2012-06-08 2016-04-06 Biogen Ma Inc INHIBITORS OF BRUTON TYROSINE KINASE
RS57662B1 (sr) * 2013-12-11 2018-11-30 Biogen Ma Inc Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
AR102426A1 (es) * 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
EP3487852A1 (en) * 2016-07-21 2019-05-29 Biogen MA Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
BR0109467A (pt) 2000-03-17 2003-06-03 Bristol Myers Squibb Pharma Co Composto derivados de (beta)-aminoácidos cìclicos, composição farmacêutica, método de tratamento de condições ou doenças mediadas por mps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso de composto
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
EP1778298A4 (en) * 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
PT1951684T (pt) 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
JP2009521445A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
JP2009544732A (ja) 2006-07-26 2009-12-17 ノバルティス アクチエンゲゼルシャフト ウンデカプレニルピロホスフェートシンターゼの阻害剤
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
CN101674831A (zh) * 2007-03-02 2010-03-17 先灵公司 用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101932580B (zh) 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
WO2009098144A1 (en) 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
ES2542066T3 (es) 2008-04-29 2015-07-30 Immunexcite, Inc. Composiciones inmunomoduladoras y métodos de uso de las mismas
MX2011000661A (es) * 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
JP5487214B2 (ja) * 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
WO2010080712A2 (en) * 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2435442B1 (de) 2009-05-25 2016-01-13 Sandoz AG Verfahren zur herstellung von ceftobiprol medocaril
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
EP2473049B1 (en) 2009-09-04 2018-11-28 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc INHIBITORS OF BRUTON TYROSINE KINASE
RS57662B1 (sr) 2013-12-11 2018-11-30 Biogen Ma Inc Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance

Also Published As

Publication number Publication date
EP2858499A4 (en) 2016-01-20
ZA201409255B (en) 2015-12-23
AU2019203476B2 (en) 2021-01-28
PH12014502699A1 (en) 2015-02-02
US20210017155A1 (en) 2021-01-21
AU2017201536B2 (en) 2019-03-07
HK1209284A1 (en) 2016-04-01
TWI592406B (zh) 2017-07-21
US10618887B2 (en) 2020-04-14
JP2017193583A (ja) 2017-10-26
EA201492056A1 (ru) 2015-05-29
HRP20181294T1 (hr) 2018-10-05
BR112014030655B1 (pt) 2021-04-20
AU2021202412A1 (en) 2021-05-20
PT2858499T (pt) 2018-10-24
JP2021073299A (ja) 2021-05-13
BR112014030655A2 (pt) 2017-06-27
MX2014015044A (es) 2015-09-22
CY1120638T1 (el) 2019-12-11
CN109305959B (zh) 2022-02-08
KR20220154850A (ko) 2022-11-22
JP6214643B2 (ja) 2017-10-18
TWI792158B (zh) 2023-02-11
IL235938A0 (en) 2015-02-01
PH12014502699B1 (en) 2015-02-02
WO2013185084A1 (en) 2013-12-12
RS57978B1 (sr) 2019-01-31
BR122021002178B1 (pt) 2022-03-22
ES2834333T3 (es) 2021-06-17
TWI719209B (zh) 2021-02-21
TW201805279A (zh) 2018-02-16
SI2858499T1 (sl) 2018-10-30
MX2019003618A (es) 2019-07-18
US9394277B2 (en) 2016-07-19
BR112014030655A8 (pt) 2018-01-02
IL235938B (en) 2020-10-29
KR20210072139A (ko) 2021-06-16
LT2858499T (lt) 2018-09-10
CN104540385A (zh) 2015-04-22
SG10201708535UA (en) 2017-11-29
AU2013271407A1 (en) 2015-01-22
EP2858499B1 (en) 2018-05-16
EP3385263B1 (en) 2020-07-22
AU2017201536A1 (en) 2017-03-23
EP2858499A1 (en) 2015-04-15
CN109305959A (zh) 2019-02-05
US20190047986A1 (en) 2019-02-14
IL277951A (en) 2020-11-30
KR102102587B1 (ko) 2020-04-22
US9944622B2 (en) 2018-04-17
SG11201408173WA (en) 2015-01-29
CN104540385B (zh) 2018-06-05
TW201410668A (zh) 2014-03-16
US20150158843A1 (en) 2015-06-11
JP2023052415A (ja) 2023-04-11
MX363672B (es) 2019-03-29
JP2015518903A (ja) 2015-07-06
EP3753934A1 (en) 2020-12-23
AR091273A1 (es) 2015-01-21
JP2019077728A (ja) 2019-05-23
CA3108186A1 (en) 2013-12-12
EA201790418A1 (ru) 2017-11-30
EP3385263A1 (en) 2018-10-10
JP2021073298A (ja) 2021-05-13
TW202142535A (zh) 2021-11-16
PH12018501463A1 (en) 2019-03-04
HUE039897T2 (hu) 2019-02-28
AU2019203476A1 (en) 2019-06-06
AU2022275504A1 (en) 2023-01-05
CA2875799A1 (en) 2013-12-12
AU2013271407B2 (en) 2016-12-08
KR102468430B1 (ko) 2022-11-21
PL2858499T3 (pl) 2019-03-29
DK2858499T3 (en) 2018-08-20
US20160304494A1 (en) 2016-10-20
CA2875799C (en) 2021-03-23
US20230174511A1 (en) 2023-06-08
CN113549055A (zh) 2021-10-26
ES2684268T3 (es) 2018-10-02
NZ702715A (en) 2016-11-25
EA027823B1 (ru) 2017-09-29
KR20200043497A (ko) 2020-04-27
KR20150036020A (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2014010849A (es) Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IN2015DN00127A (ko)
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MY160734A (en) Besylate salt of a btk inhibitor
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
IL259863B (en) Polycyclic compounds as inhibitors of proton tyrosine kinase
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MA39824A (fr) Composés azole amido-substitués
MX2019000884A (es) Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds